Active, not recruitingPhase 3NCT03037164
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
Studying Zika virus disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cerus Corporation
- Intervention
- INTERCEPT Blood System for Red Blood Cells(device)
- Enrollment
- 692 target
- Eligibility
- 4 years · All sexes
- Timeline
- 2017 – 2026
Study locations (16)
- Phoenix Children's Hospital (PCH), Phoenix, Arizona, United States
- Yale University, New Haven, Connecticut, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Grady Health System, Atlanta, Georgia, United States
- CHOA (Children's Healthcare of Atlanta), Atlanta, Georgia, United States
- University of Maryland School of Medicine, Baltimore, Maryland, United States
- C4TKs (Cure 4 The Kids), Las Vegas, Nevada, United States
- St Jude Children's Research Hospital, Memphis, Tennessee, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- Baylor St. Luke's Medical Center, Houston, Texas, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- Versiti, Wauwatosa, Wisconsin, United States
- Menonita General Hospital, Aibonito, Puerto Rico
- HIMA San Pablo Hospital, Caguas, Puerto Rico
- San Juan Bautista School of Medicine Clinical Research Unit, Caguas, Puerto Rico
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03037164 on ClinicalTrials.govOther trials for Zika virus disease
Additional recruiting or active studies for the same condition.